STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALKS
  4. [Form 4] Alkermes plc. Insider Trading Activity

Alkermes plc (NASDAQ: ALKS) grants CEO new performance and time-based options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Alkermes plc reported that President & CEO Jackson Blair Curtis received two grants of Employee Stock Options on 2026-08-05. One award covers 93,229 options with an exercise price of $49.6100 per share, vesting in four equal annual installments commencing on 8/5/2027 and expiring on 2036-08-05. A second award covers 124,305 options at the same exercise price and expiration, vesting in two tranches only if Alkermes’s ordinary share trades at certain pre-specified price levels for 30 consecutive trading days and after two years of continuous service as CEO, or less in the event of a change in control.

Positive

  • None.

Negative

  • None.
Insider Jackson Blair Curtis
Role President & CEO, Alkermes plc
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) F1, F2 93,229 $0.00 $0.00
Grant/Award Employee Stock Option (Right to Buy) F1, F3 124,305 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (Right to Buy) — 217,534 shares (Direct)
Footnotes (3)
  1. F1. This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.
  2. F2. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.
  3. F3. Shares underlying the stock option shall vest and become exercisable, if at all, in two tranches based upon the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, trading at certain pre-specified levels for 30 consecutive trading days, subject in each case to the reporting person's completion of two years of continuous service (or less, in the event of a change in control) in the role of President and Chief Executive Officer. This award expires ten years from the date of grant.
Time-based stock options granted 93,229 options Employee Stock Option grant on 2026-08-05, vesting over four years
Performance-based stock options granted 124,305 options Employee Stock Option grant on 2026-08-05 with price and service conditions
Exercise price per option $49.6100 per share Conversion or exercise price for both Employee Stock Option awards
Option expiration date 2036-08-05 Both CEO stock option awards expire ten years from the grant date
Time-vested award start 8/5/2027 Vesting of 93,229 options commences on this date in four equal installments
Service period for performance award 2 years Continuous service as President and CEO required for performance-based vesting
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
vest and become exercisable financial
"Shares underlying the stock option vest and become exercisable in four equal annual installments"
pre-specified levels financial
"trading at certain pre-specified levels for 30 consecutive trading days"
change in control financial
"or less, in the event of a change in control) in the role of President"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What stock option grants did Alkermes (ALKS) CEO Jackson Blair Curtis receive?
Jackson Blair Curtis received two Employee Stock Option awards on 2026-08-05: one for 93,229 options and another for 124,305 options, each over ordinary shares with a $49.6100 exercise price and expiration on 2036-08-05.

How do the time-based stock options for Alkermes (ALKS) CEO vest?
The time-based award of 93,229 stock options vests in four equal annual installments, commencing on 8/5/2027. Once vested, these options become exercisable at an exercise price of $49.6100 per ordinary share until 2036-08-05.

What performance conditions apply to the 124,305 Alkermes (ALKS) CEO stock options?
The 124,305 stock options vest in two tranches only if Alkermes’s ordinary shares trade at pre-specified price levels for 30 consecutive trading days, and after two years of continuous service as President and CEO, subject to change-in-control provisions.

Why were these stock options granted to the Alkermes (ALKS) CEO?
The filing states the awards were granted in connection with Jackson Blair Curtis’s appointment as President and Chief Executive Officer of Alkermes plc, aligning his compensation with company performance through equity-based incentives over a multi-year period.

What is the term of the new Alkermes (ALKS) CEO stock options?
Both stock option awards expire on 2036-08-05, giving Jackson Blair Curtis up to ten years from the grant date to exercise vested options at the $49.6100 per share exercise price, subject to each award’s vesting conditions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jackson Blair Curtis
(Last)(First)(Middle)
CONNAUGHT HOUSE
1 BURLINGTON ROAD
(Street)
DUBLIN 4 IRELAND
(City)(State)(Zip)
IRELAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO, Alkermes plc
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$49.6108/05/2026A(1)93,229 (2)08/05/2036Ordinary Shares93,229$093,229D
Employee Stock Option (Right to Buy)$49.6108/05/2026A(1)124,305 (3)08/05/2036Ordinary Shares124,305$0124,305D
Explanation of Responses:
1. This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.
2. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.
3. Shares underlying the stock option shall vest and become exercisable, if at all, in two tranches based upon the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, trading at certain pre-specified levels for 30 consecutive trading days, subject in each case to the reporting person's completion of two years of continuous service (or less, in the event of a change in control) in the role of President and Chief Executive Officer. This award expires ten years from the date of grant.
/s/ Shantale Greenson, attorney-in-fact for Blair C. Jackson08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR